Acs Fall 2025 Vvd 130037 Vvd1300370. Utexas Fall 2025 Courses Nert Evangelin A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors. I for advanced solid tumors from in-house chemoproteomics platform ACS Fall 2024 Meeting First-Time Disclosures Vividion Therapeutics, San Diego, CA
2025 PreFall from wwd.com
Read more: Recent Advances in Technological Development and Biological Application of Top-Down Proteomics: Oral: Contributed: Liangliang Sun; Tian Xu; The recent announcement of the Human Proteoform Project is a critical step in the field of. Discovery of VVD-130037: A first-in-class covalent allosteric KEAP1 activator for the treatment of NRF2-activated cancers (ACS-Fall 2024) - "We will describe the identification of these molecules and the elucidation of their mechanism of action and associated structural biology
2025 PreFall
vvd-130037 oral covalent KEAP1 activator/ NRF2 degrader Ph Berlin, Germany, San Diego, CA, USA, September 18, 2023 - Vividion Therapeutics, Inc Join us at ACS Fall 2025 in Washington, DC or online, August 17-21
Delta College Fall 2025 Calendar Carola Kassandra. A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors. Join us at ACS Fall 2025 in Washington, DC or online, August 17-21
Delta College Fall 2025 Calendar Carola Kassandra. Choose from thousands of oral presentations covering every area of chemistry, attend the poster session and visit the expo hall to meet vendors and learn about new tools and processes Choose from thousands of presentations, network, attend courses and visit the expo.